News

b

b

Current News in Drug Discovery

RSS Nature Reviews Drug Discovery
  • Neurotensin receptor modulator safely tackles pain June 20, 2025
    Nature Reviews Drug Discovery, Published online: 20 June 2025; doi:10.1038/d41573-025-00109-8Neurotensin receptor modulator safely tackles pain
    Sarah Crunkhorn
  • Neutrophil-targeting drug seeks first approval in an inflammatory lung disease June 17, 2025
    Nature Reviews Drug Discovery, Published online: 17 June 2025; doi:10.1038/d41573-025-00108-9Insmed’s DPP1 inhibitor brensocatib could become the first drug to secure an approval for bronchiectasis, and is in trials for other inflammatory diseases.
    Katie Kingwell
  • Upcoming FDA approval decisions in Q3 2025 June 16, 2025
    Nature Reviews Drug Discovery, Published online: 16 June 2025; doi:10.1038/d41573-025-00103-0Upcoming FDA approval decisions in Q3 2025
    Andrew Shui-Jezierski
  • Keeping the immuno-oncology flame burning June 13, 2025
    Nature Reviews Drug Discovery, Published online: 13 June 2025; doi:10.1038/d41573-025-00107-wIra Mellman, the new president of research at the Parker Institute for Cancer Immunotherapy, asks why so many drug developers are retreating from immune-modulating drugs, cell therapies and cancer vaccines before these modalities have achieved their full potential.
    Asher Mullard
  • Targeting DNA damage in ageing: towards supercharging DNA repair June 12, 2025
    Nature Reviews Drug Discovery, Published online: 12 June 2025; doi:10.1038/s41573-025-01212-6DNA damage to the somatic genome has been identified as a major cause of ageing. This Perspective provides an overview of current understanding of the role of genome instability in the ageing process and assesses therapeutic strategies targeting the cellular response to DNA damage to delay […]
    Arturo Bujarrabal-Dueso
  • FDA approves a c-MET-targeted ADC for lung cancer June 10, 2025
    Nature Reviews Drug Discovery, Published online: 10 June 2025; doi:10.1038/d41573-025-00104-zFDA approves a c-MET-targeted ADC for lung cancer
    Asher Mullard
  • FDA approves first-in-class TRPM8 ion channel agonist for dry eye disease June 10, 2025
    Nature Reviews Drug Discovery, Published online: 10 June 2025; doi:10.1038/d41573-025-00106-xFDA approves first-in-class TRPM8 ion channel agonist for dry eye disease
    Asher Mullard
  • PD1 × VEGF blocking bispecifics for cancer draw big backing June 10, 2025
    Nature Reviews Drug Discovery, Published online: 10 June 2025; doi:10.1038/d41573-025-00105-yPD1 × VEGF blocking bispecifics for cancer draw big backing
    Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

 BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia™.

Attending on behalf of Vitreon America™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America™ was established with the goal of commercializing their Botanicopeia™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon AmericaTM was formed with the goal of disseminating their BotanicopeiaTM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com